000289492 001__ 289492
000289492 005__ 20251023115525.0
000289492 0247_ $$2doi$$a10.1016/j.esmoop.2024.102992
000289492 0247_ $$2pmid$$apmid:38626634
000289492 0247_ $$2altmetric$$aaltmetric:162536123
000289492 037__ $$aDKFZ-2024-00814
000289492 041__ $$aEnglish
000289492 082__ $$a610
000289492 1001_ $$0P:(DE-He78)220ae95e502090f81d486cc30b17836d$$aCarrera, Pricivel$$b0$$eFirst author
000289492 245__ $$aESMO expert consensus statements on the screening and management of financial toxicity in patients with cancer.
000289492 260__ $$aLondon$$bBMJ$$c2024
000289492 3367_ $$2DRIVER$$aarticle
000289492 3367_ $$2DataCite$$aOutput Types/Journal article
000289492 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1736510217_15823
000289492 3367_ $$2BibTeX$$aARTICLE
000289492 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000289492 3367_ $$00$$2EndNote$$aJournal Article
000289492 500__ $$a#EA:B210#
000289492 520__ $$aFinancial toxicity, defined as both the objective financial burden and subjective financial distress from a cancer diagnosis and its treatment, is a topic of interest in the assessment of the quality of life of patients with cancer and their families. Current evidence implicates financial toxicity in psychosocial, economic and other harms, leading to suboptimal cancer outcomes along the entire trajectory of diagnosis, treatment, supportive care, survivorship and palliation. This paper presents the results of a virtual consensus, based on the evidence base to date, on the screening and management of financial toxicity in patients with and beyond cancer organized by the European Society for Medical Oncology (ESMO) in 2022.A Delphi panel of 19 experts from 11 countries was convened taking into account multidisciplinarity, diversity in health system contexts and research relevance. The international panel of experts was divided into four working groups (WGs) to address questions relating to distinct thematic areas: patients with cancer at risk of financial toxicity; management of financial toxicity during the initial phase of treatment at the hospital/ambulatory settings; financial toxicity during the continuing phase and at end of life; and financial risk protection for survivors of cancer, and in cancer recurrence. After comprehensively reviewing the literature, statements were developed by the WGs and then presented to the entire panel for further discussion and amendment, and voting.A total of 25 evidence-informed consensus statements were developed, which answer 13 questions on financial toxicity. They cover evidence summaries, practice recommendations/guiding statements and policy recommendations relevant across health systems. These consensus statements aim to provide a more comprehensive understanding of financial toxicity and guide clinicians globally in mitigating its impact, emphasizing the importance of further research, best practices and guidelines.
000289492 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000289492 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000289492 650_7 $$2Other$$aassessment tools
000289492 650_7 $$2Other$$acancer
000289492 650_7 $$2Other$$afinancial toxicity
000289492 650_7 $$2Other$$ahealth insurance coverage
000289492 650_7 $$2Other$$asociodemographic factors
000289492 650_7 $$2Other$$asurvivorship
000289492 7001_ $$aCurigliano, G.$$b1
000289492 7001_ $$aSantini, D.$$b2
000289492 7001_ $$aSharp, L.$$b3
000289492 7001_ $$aChan, R. J.$$b4
000289492 7001_ $$aPisu, M.$$b5
000289492 7001_ $$aPerrone, F.$$b6
000289492 7001_ $$aKarjalainen, S.$$b7
000289492 7001_ $$aNumico, G.$$b8
000289492 7001_ $$aCherny, N.$$b9
000289492 7001_ $$0P:(DE-HGF)0$$aWinkler, E.$$b10
000289492 7001_ $$aAmador, M. L.$$b11
000289492 7001_ $$aFitch, M.$$b12
000289492 7001_ $$aLawler, M.$$b13
000289492 7001_ $$aMeunier, F.$$b14
000289492 7001_ $$aKhera, N.$$b15
000289492 7001_ $$aPentheroudakis, G.$$b16
000289492 7001_ $$aTrapani, D.$$b17
000289492 7001_ $$aRipamonti, C. I.$$b18
000289492 773__ $$0PERI:(DE-600)2844985-X$$a10.1016/j.esmoop.2024.102992$$gVol. 9, no. 5, p. 102992 -$$n5$$p102992$$tESMO open$$v9$$x2059-7029$$y2024
000289492 8564_ $$uhttps://inrepo02.dkfz.de/record/289492/files/1-s2.0-S2059702924007609-main.pdf$$yOpenAccess
000289492 8564_ $$uhttps://inrepo02.dkfz.de/record/289492/files/1-s2.0-S2059702924007609-main.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000289492 909CO $$ooai:inrepo02.dkfz.de:289492$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000289492 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)220ae95e502090f81d486cc30b17836d$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000289492 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000289492 9141_ $$y2024
000289492 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-27
000289492 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-27
000289492 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-27
000289492 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bESMO OPEN : 2022$$d2023-10-27
000289492 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-04-12T14:49:18Z
000289492 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-04-12T14:49:18Z
000289492 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-27
000289492 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-10-27
000289492 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-27
000289492 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000289492 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-04-12T14:49:18Z
000289492 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-10-27
000289492 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bESMO OPEN : 2022$$d2023-10-27
000289492 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-27
000289492 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-27
000289492 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-27
000289492 9201_ $$0I:(DE-He78)B210-20160331$$kB210$$lNWG Somatische Evolution und Früherkennung$$x0
000289492 9200_ $$0I:(DE-He78)B210-20160331$$kB210$$lNWG Somatische Evolution und Früherkennung$$x0
000289492 980__ $$ajournal
000289492 980__ $$aVDB
000289492 980__ $$aUNRESTRICTED
000289492 980__ $$aI:(DE-He78)B210-20160331
000289492 9801_ $$aFullTexts